Ronald Petersen, MD, PhD, discusses the implications of the failed solanezumab trial.
Diabetics tended to have higher levels of tau protein in spinal and brain fluid irregardless of whether they had dementia.
Dementia patients on cholinesterase inhibitors had a higher risk of significant weight loss compared to those not on the drugs.
Older adults with type 2 diabetes that took pioglitazone (Actos) had about half the risk of developing dementia as non-diabetics.
Poor performance on memory and cognition tests could provide early warning signs of Alzheimer's as much as 18 years before disease is diagnosed.
Digital map of older brain created from MRI scans could be make it easier for clinicians to diagnose neurocognitive disorders earlier.
Researchers believe that the anti-hypertensive medications people with high blood pressure take may play a role in decreasing Alzheimer's risk.
Abnormal levels of lysosomal proteins could provide a way to diagnose and treat Alzheimer's disease years before onset of symptoms.
However, people who kept busy with mental activities had better cognitive performance than those who didn't.
Patients who were taking tacrolimus or cyclosporine after organ transplant had significantly lower rates of Alzheimer's compared to general public.
Psychiatry Advisor Articles
- Naltrexone-Assisted Detox vs Buprenorphine Taper for Opioid Dependence
- Suicide Prevention and Intervention: Cross-Cultural Perspectives
- Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment
- Which Antidepressants May Cause Birth Defects?
- Best Practices for Treatment of Bipolar Disorder